ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
ALPS Medical Breakthroughs ETF SBIO
Morningstar’s Analysis SBIO
Will SBIO outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 31.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
CG Oncology Inc | 3.92 | 7M | Healthcare |
Oruka Therapeutics Inc | 3.63 | 6M | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 3.59 | 6M | Healthcare |
Veradermics Inc | 3.39 | 6M | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 3.29 | 6M | Healthcare |
Dianthus Therapeutics Inc | 2.99 | 5M | Healthcare |
Edgewise Therapeutics Inc | 2.87 | 5M | Healthcare |
Relay Therapeutics Inc Ordinary Shares | 2.67 | 5M | Healthcare |
Amylyx Pharmaceuticals Inc | 2.42 | 4M | Healthcare |
Acadia Pharmaceuticals Inc | 2.37 | 4M | Healthcare |